AI Article Synopsis
- A 64-year-old woman with severe myocarditis was treated with advanced life support devices, including veno-arterial ECMO and Impella systems, over a 3-month period while also undergoing continuous hemodiafiltration.
- During her treatment, she developed myelodysplastic syndrome, characterized by anemia and low platelet counts, but improved after device removal and stopped needing blood transfusions.
- Ultimately, she received a HeartMate 3 left ventricular assist device without the use of aspirin for blood thinning, successfully managing the condition for 4 months post-discharge without bleeding issues.
Article Abstract
We encountered a 64-year-old woman who experienced fulminant myocarditis and underwent treatment with veno-arterial extracorporeal membrane oxygenation and Impella CP support. Subsequently, she underwent a device upgrade to Impella 5.5 and received continuous hemodiafiltration for 3 months. During mechanical circulatory support, she developed refractory anemia and thrombocytopenia, leading to a diagnosis of myelodysplastic syndrome. Following the removal of the devices, she no longer required blood transfusions. She received HeartMate 3 left ventricular assist device implantation as a destination therapy indication despite the presence of myelodysplastic syndrome. She was successfully managed by aspirin-free antithrombotic therapy without any hemocompatibility-related adverse events for 4 months after index discharge on foot. We present a patient with a unique and rare presentation, wherein HeartMate 3 was implanted and successfully managed without aspirin to prevent bleeding complications associated with myelodysplastic syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10047-024-01455-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!